News Sentiment

BCAB sentiment intelligence

Bioatla Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.82 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-8.8% over one week, -1.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

BioAtla: BioAtla, Inc. - Reverse Split Option Symbol: BCAB New Symbol: BCAB1

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -8.8% Price reacting lower
Trend fit Trend inactive -1.0% over four weeks
Fair value -93.6% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 41
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 9
TradingKey 7
Market source 6
TradingView 6
Moomoo 4
Investing.com 4
simplywall.st 3
Investing News Network 3

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 15
Deals and strategy 4
Regulatory and legal 2
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 52
Moomoo Direct company coverage

BioAtla: BioAtla, Inc. - Reverse Split Option Symbol: BCAB New Symbol: BCAB1

This document announces that BioAtla, Inc. (BCAB) has undergone a reverse split, and a new option symbol, BCAB1, has been introduced. The article title and content solely focus on this corporate action.

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 22:41
Source
Moomoo
TradingView Direct company coverage

Enterprise value to revenue forward of BioAtla, Inc. – NASDAQ:BCAB

The article discusses the enterprise value to revenue forward for BioAtla, Inc. (NASDAQ: BCAB). It appears to be a financial listing or data point from a trading platform, providing a specific value for this financial metric during a particular period.

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:41
Source
TradingView
TradingView Direct company coverage

BioAtla, Inc. Actuals & Estimates (NASDAQ:BCAB)

This article provides an overview of BioAtla, Inc. (NASDAQ: BCAB) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers key metrics such as market capitalization, volatility, net income, and upcoming earnings dates, offering

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 18:41
Source
TradingView
TradingKey Direct company coverage

Bioatla Inc (BCAB) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Bioatla Inc (BCAB), highlighting its current valuation score of 9.98, which ranks 1st in the Biotechnology & Medical Research industry. It notes the company's P/E ratio is -0.02, significantly above its recent low. However, key P/B,

Tone
Neutral 50/100
Event
Market update
Published
23 Jun 2026 06:11
Source
TradingKey
TradingKey Direct company coverage

Bioatla Inc (BCAB) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Bioatla Inc (BCAB), detailing its price momentum, support and resistance levels, and indicator and moving average signals. Currently, BCAB has a price momentum score of 7.42, trading between a resistance of $4.23 and support of $3.13,

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 08:09
Source
TradingKey
TradingKey Direct company coverage

Bioatla Inc (BCAB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a revenue breakdown for Bioatla Inc (BCAB) but states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. It briefly shows the stock's current trading status and market capitalization

Tone
Neutral 50/100
Event
Earnings
Published
19 Jun 2026 03:11
Source
TradingKey
TradingKey Direct company coverage

Bioatla Inc (BCAB) Dividends & Stock Splits: Historical Payouts and Event Timeline

The article provides an overview of Bioatla Inc.'s (BCAB) dividend and stock split history. It indicates that BCAB has not distributed any dividends over the past five years. However, it lists a significant stock split event planned as a 50-to-1 merger on March 31, 2026.

Tone
Neutral 50/100
Event
Deals and strategy
Published
19 Jun 2026 02:11
Source
TradingKey
TradingKey Direct company coverage

Bioatla Inc (BCAB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Bioatla Inc (BCAB) has an earnings forecast score of 10.00, placing it first in the Biotechnology & Medical Research industry. Analysts predict a strong buy trend with an average price target of $10.00, suggesting a significant upside. The company's recent EPS was -$8.18, with th

Tone
Positive 70/100
Event
Earnings
Published
18 Jun 2026 01:39
Source
TradingKey
Moomoo Direct company coverage

BioAtla | 4: Statement of changes in beneficial ownership of securities-Officer Sievers Eric

This article is a statement of changes in beneficial ownership of securities for BioAtla, specifically concerning an officer named Sievers Eric. It is a regulatory filing indicating modifications in the individual's holdings of company securities.

Tone
Neutral 50/100
Event
Regulatory and legal
Published
10 Jun 2026 03:09
Source
Moomoo
Stock Titan Direct company coverage

BioAtla (BCAB) CMO has 494 shares withheld to cover RSU taxes

BioAtla, Inc.'s Chief Medical Officer, Eric Sievers, had a total of 494 common shares withheld to cover income tax obligations related to vested restricted stock units. These transactions, occurring on March 11, 2026, and May 31, 2026, were tax-related share withholdings and not

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

BioAtla (NASDAQ: BCAB) CEO reports routine tax-share withholdings after RSU vesting

BioAtla, Inc. CEO Jay M. Short reported routine tax-related share dispositions following the vesting of restricted stock units (RSUs), not open-market sales. A total of 898 common shares were withheld by the company to cover income tax obligations across two dates in March and Ma

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

BioAtla (NASDAQ: BCAB) CFO logs non-sale share withholdings for RSU taxes

BioAtla (NASDAQ: BCAB) Chief Financial Officer Christian Vasquez reported routine tax-withholding transactions concerning restricted stock units, not open-market stock sales. A total of 257 common shares were withheld by the company on two separate dates in 2026 to cover income t

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:11
Source
Stock Titan
Moomoo Direct company coverage

BioAtla | DEFA14A: Others

This article provides access to the DEFA14A document filed by BioAtla, which is a definitive additional soliciting material.

Tone
Neutral 50/100
Event
Market update
Published
04 Jun 2026 15:39
Source
Moomoo
Stock Titan Direct company coverage

BioAtla (NASDAQ: BCAB) schedules 2026 virtual meeting and pay vote

BioAtla (NASDAQ: BCAB) has scheduled its 2026 Annual Meeting of Stockholders for July 16, 2026, to be held virtually. Shareholders will vote on the election of two Class III directors, the ratification of Ernst & Young LLP as the independent auditor, and a non-binding advisory vo

Tone
Neutral 50/100
Event
Market update
Published
03 Jun 2026 19:39
Source
Stock Titan
Finviz Direct company coverage

BCAB - BioAtla Inc Stock Price and Quote

This page provides a comprehensive overview of BioAtla Inc. (BCAB) stock, including its latest stock price, financial metrics, analyst ratings, and recent news. It covers key financial data such as market cap, income, sales, and various ratios, alongside insider ownership and ins

Tone
Neutral 50/100
Event
Analyst action
Published
01 Jun 2026 09:10
Source
Finviz
Sahm Direct company coverage

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

Context Therapeutics has amended its exclusive license agreement with BioAtla for CT-202, eliminating future milestone and royalty obligations in exchange for an upfront payment of $4.5 million and a final payment of $2.0 million. This amendment grants Context Therapeutics full e

Tone
Positive 60/100
Event
Market update
Published
20 May 2026 03:10
Source
Sahm
Moomoo Direct company coverage

Context Therapeutics Secures Full Rights to CT-202 Under Revised BioAtla Deal

Context Therapeutics has gained full rights to CT-202 following a revised agreement with BioAtla. The article also briefly mentions Unity Software's Q4 financial results, including a 35% revenue increase year-over-year to $609 million and a quarterly loss of 66 cents per share.

Tone
Neutral 50/100
Event
Earnings
Published
18 May 2026 11:39
Source
Moomoo
TradingView Direct company coverage

Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free

Context Therapeutics has entered into an amendment with BioAtla to convert its antibody licenses, including CT-202, into irrevocable, royalty-free, fully paid-up, and non-terminable rights for $6.5 million. This agreement eliminates Context's R&D and reporting obligations, remove

Tone
Positive 66/100
Event
Market update
Published
18 May 2026 11:10
Source
TradingView
Stock Titan Direct company coverage

Context to pay $6.5M for full CT-202 rights by Aug. 1, 2026

Context Therapeutics has amended its license agreement with BioAtla for CT-202, converting it into a fully paid-up, non-terminable license. This agreement eliminates all future CT-202 milestones and royalties for a total of $6.5 million, with $4.5 million upfront and a final $2.0

Tone
Positive 65/100
Event
Market update
Published
18 May 2026 11:10
Source
Stock Titan
Stock Titan Direct company coverage

Context Therapeutics (CNTX) secures fully paid-up, non-terminable CT-202 license

Context Therapeutics (CNTX) has amended its license agreement with BioAtla for its CT-202 program, making the license royalty-free, fully paid-up, and non-terminable in exchange for upfront payments totaling $6.5 million. This agreement gives Context full economic rights to CT-20

Tone
Neutral 50/100
Event
Market update
Published
18 May 2026 11:10
Source
Stock Titan
TradingView Direct company coverage

Number of shareholders of BioAtla, Inc. – NASDAQ:BCAB

This article provides details on the number of shareholders for BioAtla, Inc. (NASDAQ: BCAB). It is presented on a TradingView page, indicating current market status and offering various financial tools and data. The core content focuses on shareholder figures, though the specifi

Tone
Neutral 50/100
Event
Market update
Published
14 May 2026 17:40
Source
TradingView
TradingKey Direct company coverage

TradingKey

This page provides an overview of Bioatla Inc (BCAB) stock performance, including its current price, market capitalization, and P/E TTM. The site offers various financial market data, news, analysis tools, and educational resources. It also includes sections for user comments and

Tone
Negative 30/100
Event
Market update
Published
11 May 2026 14:39
Source
TradingKey
Simply Wall Street Direct company coverage

BioAtla (Nasdaq:BCAB) - Stock Analysis

BioAtla (Nasdaq:BCAB) is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for solid tumor cancer. The company's stock has shown high volatility and significant decline over the past year, with ongoing concerns about cash burn, sharehold

Tone
Neutral 50/100
Event
Balance sheet
Published
06 May 2026 23:10
Source
Simply Wall Street